Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).

Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007 Oct; 25(5):445-51.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Angiogenesis Inhibitors
Antineoplastic Agents
Humans
Male
Maximum Tolerated Dose
Middle Aged
Prostate-Specific Antigen
Prostatic Neoplasms
Protein-Tyrosine Kinases
Quinazolines
Vascular Endothelial Growth Factor Receptor-1

authors with profiles

Walter M. Stadler